Revelation Partners provides flexible capital solutions for healthcare companies and their shareholders. The firm manages $1.5 billion in assets, has over 50 active portfolio companies, and claims a total value of exited companies exceeding $100 billion.

Revelation Partners

Revelation Partners provides flexible capital solutions to the healthcare ecosystem. We specialize in providing liquidity for illiquid, private holdings to eliminate friction and capital to accelerate growth. We invest broadly across all healthcare sub-sectors, including medical devices, life science tools and diagnostics, biopharmaceuticals, healthcare technology, and healthcare services. With decades of investing experience, deep sector expertise, an extensive industry network, and over $1.5bn of committed capital, Revelation Partners is a trusted partner to healthcare investors, companies, and funds.

SomaLogic

ClearCorrect

NeuroPace

We’re thrilled to congratulate our portfolio company Vertos Medical on its acquisition by global medical technologies leader Stryker! Vertos’ innovative procedure for lumbar spinal stenosis — which is a leading cause of pain and disability — is minimally invasive with high lasting relief rates and reduced recovery times. 

“Allowing patients to get back to what matters most to them is what matters most to us,” said Eric Wichems, Vertos Medical’s Chief Executive Officer. “Stryker’s mission and focus on interventional solutions provides an opportunity to further improve patients' quality of life.” 
 
Read more about the acquisition agreement here: https://lnkd.in/dsJ85nU9

Check out our latest blog post, written by Garrett B., where we take a deep dive into into the #fundraising environment for emerging managers, and assess why emerging managers in #healthcare stand to disproportionately benefit from building a track record of distributions via a secondary toolkit:

https://lnkd.in/g8jc_vfu

Interested in learning about secondary transactions in healthcare private equity? Read our latest white paper written in partnership with Darren Schluter and Danny Schuster from PJT Partners Park Hill:

#privateequity #secondaries #healthcare

https://lnkd.in/gyXHWaC9

Check out our interview with Gerald Cooper for our blog series 
"Secondary Spotlight," where we interview some of the leading secondary advisors in the industry:

https://lnkd.in/gdCsyRZu

In this fifth (and final) release in a series of interviews with successful figures in the venture capital secondary market, Derek Minno talks with Michael Boggs, Managing Partner at Revelation Partners, on healthcare secondaries.

“Last year we invested over $190 million across all healthcare segments, which is 6x what we did in our first year as Revelation, so the dynamic has really changed, and the market is really exploding in terms of growth in every dimension,” Boggs said.

This article features Derek's takeaways from the conversation along with his own insights, as written by Derek himself. 

Take a look!

#Secondaries #Secondary #SecondaryMarket #AlternativeInvestments #PrivateMarkets #Venture #VentureCapital #VC

"Immuno-oncology company Nouscom AG has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its pipeline of personalized and off-the-shelf cancer vaccines."

https://lnkd.in/gJqRrzvy

We're thrilled to welcome Courtney Munley and Paden Rasmussen to the team, and also celebrate the growth of internal talent: 

https://lnkd.in/grbfdDfF

Check out our interview with Todd Miller for our new blog series 
"Secondary Spotlight," where we interview some of the leading secondary advisors in the industry:

https://lnkd.in/gjbq3Y_3

Metric
Company Name	Revelation Partners
Symbol
MSH ID	COM:REVELATION-PARTNERS
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Investment Management
Country	US
Stage
Employee Count
Website	revelation-partners.com
LinkedIn	revelation-partners
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

REVE

COM:REVELATION-PARTNERS

Revelation Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue